Cetera Investment Advisers Catalyst Pharmaceuticals, Inc. Transaction History
Cetera Investment Advisers
- $49.2 Billion
- Q1 2025
A detailed history of Cetera Investment Advisers transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Cetera Investment Advisers holds 58,180 shares of CPRX stock, worth $1.48 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
58,180
Previous 43,114
34.94%
Holding current value
$1.48 Million
Previous $899,000
56.84%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CPRX
# of Institutions
389Shares Held
99.3MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$474 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$215 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$140 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$86.8 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$79.5 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.61B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...